Journal article
Methylation Signature Implicated in Immuno-Suppressive Activities in Tubo-Ovarian High-Grade Serous Carcinoma
C Wang, MS Block, JM Cunningham, ME Sherman, BM McCauley, SM Armasu, RA Vierkant, N Traficante, A Talhouk, SJ Ramus, N Pejovic, M Kobel, BD Jorgensen, DW Garsed, S Fereday, JA Doherty, D Ariyaratne, MS Anglesio, M Widschwendter, T Pejovic Show all
Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2023
Abstract
Background: Better understanding of prognostic factors in tuboovarian high-grade serous carcinoma (HGSC) is critical, as diagnosis confers an aggressive disease course. Variation in tumor DNA methylation shows promise predicting outcome, yet prior studies were largely platform-specific and unable to evaluate multiple molecular features. Methods: We analyzed genome-wide DNA methylation in 1,040 frozen HGSC, including 325 previously reported upon, seeking a multi-platform quantitative methylation signature that we evaluated in relation to clinical features, tumor characteristics, time to recurrence/death, extent of CD8þ tumor-infiltrating lymphocytes (TIL), gene expression molecular subtypes, ..
View full abstractRelated Projects (2)
Grants
Awarded by National Institutes of Health
Funding Acknowledgements
E.L. Goode was supported by the National Cancer Institute (P50-CA136393, R01-CA248288, P30-CA015083) . AOCS: The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants and all clinical and scienti fi c collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org. We would like to thank all the women who participated in these research programs. We gratefully acknowledge the Departments of Gynecological Oncology, Medical Oncology and Anatomical Pathology at Westmead Hospital, Sydney. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17 - 01 - 1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania, and The Cancer Foundation of Western Australia (Multi -State Applications 191, 211, and 182) and the National Health and Medical Research Council of Australia (NHMRC; ID199600; ID400413, and ID400281) . The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The Gynaecological Oncology Biobank at Westmead (GynBiobank) , a member of the Australasian Biospecimen Network -Oncology group, was funded by the National Health and Medical Research Council of Australia (ID 310670 and ID 628903) and the Cancer Institute NSW (12/RIG/1 - 17 and 15/RIG/1 - 16) . D.W. Garsed is supported by NHMRC Ideas Grant (APP1186505) . D.D.L. Bowtell is supported by a National Health and Medical Research Council (NHMRC) Fellowship (APP1117044) and Program Grant (APP1092856) . OHSU: Sherie Hildreth Ovarian Cancer (SHOC) Foundation. UCL: European Union ? s Horizon 2020 European Research Council Program, H2020 BRCA-ERC under grant agreement no. 742432. Other data: National Institutes of Health/National Cancer Institute (NCI) grant R01-CA172404.